Literature DB >> 2227271

Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital.

G D'Amico1, L Montalbano, M Traina, R Pisa, M Menozzi, C Spanò, L Pagliaro.   

Abstract

In a prospective study of the natural history of congestive gastropathy, 212 consecutive cirrhotic patients (75 treated with sclerotherapy) were included. Mean follow-up was 46 months. Mild gastropathy (mosaiclike pattern) was found in 110 patients and severe gastropathy (granular mucosa with cherry spots) was found in 20. Prevalence of Helicobacter pylori, formerly Campylobacter pylori, was 50% in patients without, 43% in those with mild, and 28% in those with severe gastropathy. Congestive gastropathy was significantly more frequent in patients treated with sclerotherapy (83% vs. 50%, P less than 10(-5)). Sixty-month actuarial proportions of patients free of anemia (in the absence of hematemesis or melena), were 17% with severe, 62% with mild, and 93% without gastropathy (P less than 10(-8]. Corresponding figures for overt bleeding were 25%, 73%, and 87% (P less than 10(-7], whereas those for survival were 46%, 72%, and 85% (P = 0.0005), respectively. A multivariate regression analysis supported the following conclusions: (a) sclerotherapy and the presence of large esophageal varices significantly increase the risk of congestive gastropathy, which (b) is a significant risk indicator of both chronic and overt bleeding but does not independently affect survival.

Entities:  

Mesh:

Year:  1990        PMID: 2227271     DOI: 10.1016/0016-5085(90)90458-d

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  32 in total

Review 1.  Non-variceal gastrointestinal bleeding in patients with liver cirrhosis: a review.

Authors:  M Kalafateli; C K Triantos; V Nikolopoulou; A Burroughs
Journal:  Dig Dis Sci       Date:  2012-06-04       Impact factor: 3.199

2.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

3.  Effects of esophageal varice eradication on portal hypertensive gastropathy and fundal varices: a retrospective and comparative study.

Authors:  Osman Yüksel; Seyfettin Köklü; Mehmet Arhan; Omer Faruk Yolcu; Ibrahim Ertuğrul; Bülent Odemiş; Emin Altiparmak; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

4.  Gastric mucosal resistance to acute injury in experimental portal hypertension.

Authors:  S Calatayud; M C Ramírez; M J Sanz; L Moreno; C Hernández; J Bosch; J M Piqué; J V Esplugues
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Congestion of superior mesenteric veins and small bowel mucosal injury after endoscopic treatment of esophageal varices in patients with portal hypertension.

Authors:  H Toyoda; M Nakao; Y Ogura; K Takagi; K Osakabe; Y Horiguchi; H Imai; H Sakamoto; H Uno; M Kamiya; H Nakano
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

6.  Portal hypertensive gastropathy after variceal eradication: more bleeding risk or just more reddening?

Authors:  Massimo Primignani; Giulia Tosetti
Journal:  Hepatol Int       Date:  2016-06-09       Impact factor: 6.047

Review 7.  Management of gastropathy and gastric vascular ectasia in portal hypertension.

Authors:  Cristina Ripoll; Guadalupe Garcia-Tsao
Journal:  Clin Liver Dis       Date:  2010-05       Impact factor: 6.126

8.  Gastric epithelial cell proliferation in patients with liver cirrhosis.

Authors:  A Zullo; A Romiti; V Rinaldi; A Vecchione; C Hassan; S Winn; S Tomao; A F Attili
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 9.  Gastric antral vascular ectasia causing severe anemia.

Authors:  M Toyota; Y Hinoda; N Nakagawa; Y Arimura; S Tokuchi; A Takaoka; S Kitagawa; T Usuki; T Yabana; A Yachi; K Imai
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

10.  Combined (short-term plus longterm) sclerotherapy v short-term only sclerotherapy: a randomised prospective trial.

Authors:  M Moretó; M Zaballa; E Ojembarrena; S Ibáñez; M J Suárez; F Setién; E Delgado
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.